Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
about
Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV InfectionHIV testing in 2006: issues and methods.A pilot study on screening blood donors with individual-donation nucleic acid testing in China.Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.Clinical applications of molecular biology for infectious diseasesReducing the risk of hepatitis B virus transfusion-transmitted infectionPlasma for fractionation: safety and quality issues.Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.A novel approach to detect test-seeking behaviour in the blood donor population: making the invisible visible.Impact of using different blood donor subpopulations and models on the estimation of transfusion transmission residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in Zimbabwe.Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations.A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.Validation and assessment of a blood-donor arm disinfectant containing chlorhexidine and alcohol.Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis.The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria.Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential implications for screening algorithms.Estimating the risk of blood donation associated with HIV risk behaviours.Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening applyReplyPrevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) surveyResidual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives
P2860
Q27471998-9F8EAFDB-C3B3-4683-B745-1ABD77071B03Q30357130-CB8C6D60-108D-4A42-B4E4-7591786B5AD5Q33690837-EDBD0546-65D9-47DD-822D-1AB3B14A1AC9Q34346207-F805A20C-185D-4D54-82B2-BBBE2DBE989BQ34427297-3A4014A3-B881-4854-AA44-A9B6855DC335Q35683881-F4343F6C-A603-4BF6-B457-70656061416BQ35824851-EC3F7563-DB59-4553-A1D4-01DD7E69BB88Q36078723-23EF3E18-C787-45BA-A66D-63D9F14845ECQ36466447-EFA4D9F5-6D6D-47CA-80AB-33F92ED3BC3EQ39696336-F1D3F625-8E81-403B-BF9E-29E058B2AF1FQ40071178-AA1559ED-2688-41A5-91CD-449D3644556FQ40169707-5B2D8F1B-F74A-4423-8E5F-99C64CA9C987Q40383406-1D8FCEC4-3192-4435-8717-98E9BA0DAD42Q41692988-541FD1C2-97EF-4703-A27D-CB8EEF6A39C6Q41928215-9D1126BF-1444-4E7D-B551-128AD3AA02B2Q42257442-0824D013-EA5E-4152-A209-5ADFF6C42EABQ42863755-A86C9095-3D20-4AD0-845B-0A9007E0A26DQ42977855-3E511CEC-E583-48AB-A9F1-A6181905D5BDQ42997289-185E461A-FAF8-45DC-99B3-E7F26FEF18A2Q43036225-EA5FA725-5FD3-45A6-AE31-C9BDC9DE8605Q43041881-18E09195-8A03-4C7A-9BE2-F9CBD841D0BDQ43047999-C678AE94-2C2C-4479-874A-44A8E5056EA6Q44775481-8322F3C1-97A5-4F3F-8695-648E5AAD3A04Q44931522-0C8580E3-1C84-4346-9655-D6FAB8A2059FQ44986661-5644A3F7-C70B-4561-85BD-158817CB388FQ45409042-E40D92B1-0CAC-465D-B3EF-0DBA1B90E3CBQ46854672-FDD3A8AC-EF7F-4426-8550-192BDF46B9B4Q48004110-AB1E4994-5A4F-400D-8381-81832965603DQ48081521-42756929-2832-4D7E-90C5-454D7EE115DAQ50494525-D6C4C8BB-D95E-436F-8F68-D07B0E579B2CQ51714840-8069CF61-D152-4EB7-9C69-4F757BAD3154Q57176158-C0712027-D870-4C28-945A-000404EC2DE6Q57176198-ADED5AF0-2475-4F27-A7AC-2BBE359604ADQ58776091-FF55A276-249D-4920-95A7-EA1C587549BBQ58999805-1F2C52C9-B667-43DA-8A73-706BA77CEA53
P2860
Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Assessing the accuracy of thre ...... plications for future HBV NAT.
@en
type
label
Assessing the accuracy of thre ...... plications for future HBV NAT.
@en
prefLabel
Assessing the accuracy of thre ...... plications for future HBV NAT.
@en
P2093
P2860
P1433
P1476
Assessing the accuracy of thre ...... plications for future HBV NAT.
@en
P2093
Anthea Cheng
Anthony J Keller
Philip Kiely
Susan L Ismay
Trevor J Cobain
Virology Subcommittee of the N ...... ralian Red Cross Blood Service
Wayne V Bolton
P2860
P304
P356
10.1046/J.1537-2995.2002.00204.X
P577
2002-10-01T00:00:00Z